MedTrace Logo

Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients

NCT01779531 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 640

Last updated 2013-01-30

No results posted yet for this study

Summary

Human epidermalgrowth factor receptor-2(HER2) negative Luminal B subtype breast cancer patients are included. After 4 cycles of Capecitabine combined with Docetaxel(XT) protocol neoadjuvant chemotherapy ,those who reach partial response(PR) but not pathological complete response(pCR) are randomly divided into the group treated with XT protocol and the group with Capecitabine combined with Epirubicin and Cyclophosphamide(XEC) protocol ,then compare the disease free survival(DFS) and overall survival(OS) of two subgroup.

Conditions

  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Sponsors & Collaborators

  • Chinese Anti-Cancer Association

    collaborator OTHER

  • Guangzhou General Hospital of Guangzhou Military Command

    collaborator OTHER

  • Guangzhou First People's Hospital

    collaborator OTHER

  • Guangdong Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Liao Ning, MD,PhD · Guangdong Academy of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-06-30
Completion
2015-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01779531 on ClinicalTrials.gov